G9a inhibition by CM-272: Developing a novel anti-tumoral strategy for castration-resistant prostate cancer using 2D and 3D in vitro models-Reference-Cited by-同舟云学术

G9a inhibition by CM-272: Developing a novel anti-tumoral strategy for castration-resistant prostate cancer using 2D and 3D in vitro models

Published:2022-06 Issue: Volume:150 Page:113031
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Moreira-Silva Filipa,Outeiro-Pinho Gonçalo,Lobo João,Guimarães Rita,Gaspar Vítor M.,Mano João F.,Agirre Xabier,Pineda-Lucena António,Prosper Felipe,Paramio Jesus M.,Henrique Rui,Correia Margareta P.,Jerónimo Carmen

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference44 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

2. Genetics and biology of prostate cancer;Wang;Genes Dev.,2018

3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer;Heidenreich;Eur. Urol.,2014

4. Development and prevalence of castration-resistant prostate cancer subtypes;Vellky;Neoplasia,2020

5. Epigenetics in prostate cancer: biologic and clinical relevance;Jeronimo;Eur. Urol.,2011

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. G9a in Cancer: Mechanisms, Therapeutic Advancements, and Clinical Implications;Cancers;2024-06-08

2. Discovery of the First-in-Class G9a/GLP PROTAC Degrader;Journal of Medicinal Chemistry;2024-04-11

3. Discovery of the First-in-class G9a/GLP PROTAC Degrader;2024-02-29

4. EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors;Andrology;2024-02-21

5. A “One Arrow Three Eagle” Strategy to Improve CM‐272 Primed Bladder Cancer Immunotherapy;Advanced Materials;2023-12-15